Clinical Trial Update: Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients [Phase 2]

View source ↗

Summary

Phase 2 trial comparing deferasirox with subcutaneous deferoxamine in patients with sickle cell disease and iron overload; results were posted in 2011.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemolytic Anemia
• Iron Overload
• Sickle Cell Disease

Drugs mentioned

• Deferasirox (Deferasirox)
• Deferoxamine (deferoxamine)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Sickle Cell Disease, Iron Overload | Phase 2 | Status: COMPLETED | Results posted: 2011-05-02